黑料不打烊

Canada Nuclear Imaging Market Trends and Insights

Growing Prevalence of Cancer & CVD

Canada registered 247,100 new cancer cases and 88,100 cancer deaths in 2024, while 2.4 million adults live with cardiovascular disease, a burden that is reshaping diagnostic pathways.^{[1]Canadian Cancer Society, 鈥淐anadian Cancer Statistics 2024,鈥� Canadian Cancer Society, cancer.ca} FDG PET/CT stays central for non-small-cell lung cancer staging, whereas gallium-68 PSMA PET is now displacing conventional imaging for intermediate- and high-risk prostate cancer after Health Canada cleared Pluvicto in 2022.^{[2] Health Canada, 鈥淣otice of Compliance: Pluvicto,鈥� Government of Canada, canada.ca} Rubidium-82 cardiac PET attracts cardiology departments because it delivers 75% less radiation than technetium-99m SPECT. Cancer Care Ontario plans six additional PET scanners by 2028, reinforcing capacity in underserved regions.The Canada nuclear imaging market therefore enjoys a 1.8-percentage-point CAGR lift tied directly to disease-burden growth.

Rising Adoption of Hybrid PET/CT & SPECT/CT

The 2022鈥�2023 Canadian Medical Imaging Inventory listed 60 PET/CT and 331 SPECT/CT units compared with 210 standalone SPECT cameras that now average 13.2 years of service.^{[3]Canadian Agency for Drugs and Technologies in Health, 鈥淐anadian Medical Imaging Inventory 2021-2022,鈥� CADTH, cadth.ca} Integrated scanners shorten time-to-diagnosis and reduce interpretive uncertainty because anatomical and functional data are co-registered in one session. New digital platforms such as GE HealthCare鈥檚 Omni Legend and Siemens Healthineers鈥� Biograph Vision Quadra increase photon sensitivity two- to three-fold, which translates into 50% lower dose or 40% faster acquisitions. Provincial health authorities in Nova Scotia and British Columbia funded digital SPECT/CT installations in 2024, signaling growing willingness to back premium technology. Rising hybrid adoption contributes an additional 1.5-percentage-point lift to the Canada nuclear imaging market CAGR.

Government Investments in Radiopharmaceutical Capacity

After the National Research Universal reactor closed in 2018, Canada pivoted towards cyclotron-based isotope production. TRIUMF obtained CAD 35 million (USD 26 million) in 2023 to develop a national isotope ecosystem that includes gallium-68 and actinium-225. British Columbia鈥檚 CAD 32 million cyclotron and Alberta鈥檚 Calgary Radiopharmaceutical Centre, under construction through 2027, decentralize supply and shorten delivery times for short-lived tracers. BWXT Medical鈥檚 Target Delivery System at Darlington gained a license in 2023 and now produces molybdenum-99, yttrium-90, and indium-111. These projects raise domestic self-sufficiency and add 1.2 percentage points to the market鈥檚 forecast CAGR.

Digital Detector Innovations Lowering Dose

Cadmium zinc telluride detectors in SPECT and silicon photomultiplier arrays in PET convert photons to electrical signals with higher efficiency, doubling photon sensitivity and sharpening energy resolution. The Queen Elizabeth II Health Sciences Centre documented a 40% technetium-99m dose reduction for myocardial perfusion studies after installing a GE StarGuide SPECT/CT in 2024. Nanaimo Regional General Hospital achieved similar results, halving bone-scan acquisition time while expanding daily capacity. Dose optimization aligns with Health Canada radiation-safety guidelines and partially offsets workforce shortages, delivering a 0.9-percentage-point CAGR boost.

Radio-Isotope Supply Risks Post-NRU Closure

With domestic molybdenum-99 production absent until BWXT Medical鈥檚 ramp-up hits full stride, many hospitals still depend on South African and European reactors for technetium-99m generators. Transport disruptions can delay deliveries of isotopes whose half-life is just six hours, forcing postponement of non-urgent scans. TRIUMF鈥檚 direct cyclotron production, though approved, satisfies only a fraction of national demand. British Columbia and Alberta projects will narrow the gap by 2027, but Atlantic provinces and northern territories will remain vulnerable to weather-related shipping delays. The result is a -1.1 percentage-point drag on the Canada nuclear imaging market CAGR.

High Capex & Opex of Hybrid Scanners

PET/CT units cost USD 1.8 million鈥�3.5 million, SPECT/CT units require USD 1.5 million鈥�2.5 million, and annual service contracts can top USD 0.5 million. Utilization below about 1,200 scans per year risks negative returns, a barrier for smaller hospitals. Forty-one percent of PET/CT systems already exceed ten years of age, signaling deferred replacement cycles. Leasing mitigates upfront cost yet raises lifetime expense by 20%鈥�30%. Consequently, capital constraints subtract 0.8 percentage points from the Canada nuclear imaging market鈥檚 trend growth.

Segment Analysis

By Modality: Hybrid Platforms Sustain Leadership While PET/MR Accelerates

Hybrid PET/CT generated 39.35% of modality revenue in 2025, underlining its entrenched role in oncology staging and therapy response. Stand-alone SPECT cameras are declining as hospitals pivot to hybrid SPECT/CT systems that offer both functional and anatomical data without requiring patient relocation. The Canada nuclear imaging market size for hybrid PET/CT modalities is projected to climb at the overall 6.28% CAGR, whereas hybrid PET/MR leads with a 10.24% CAGR due to superior soft-tissue contrast essential for neuro-oncology and inflammatory bowel disease. Equipment makers have responded: GE HealthCare鈥檚 32 cm-axial Omni Legend shortens total-body scan time to 12 minutes, and Siemens Healthineers鈥� 106 cm-axial Biograph Vision Quadra enables simultaneous multi-organ pharmacokinetics for theranostic dosimetry. Digital cadmium zinc telluride detectors in next-generation SPECT/CT deliver twice the photon sensitivity of legacy photomultiplier tubes, permitting 50% dose cuts that help labs meet dose-optimization mandates. Hospitals in Halifax and Nanaimo adopted such systems in 2024, evidencing readiness to pay premium prices when dose savings and higher throughput combine. As old SPECT fleets age out鈥攖he average system is 13.2 years鈥攖he Canada nuclear imaging market share held by hybrid scanners will keep widening.

Note: Segment shares of all individual segments available upon report purchase

By Component: Equipment Still Dominates Yet Software Gains Momentum

Equipment captured 63.63% of component revenue in 2025 because several provinces budgeted for hybrid-scanner replacements, but software subscriptions are rising at 9.57% annually as AI-driven image-reconstruction and lesion-quantification tools become standard. The Canada nuclear imaging market size tied to software is therefore growing faster than hardware even though suppliers often bundle first-year licenses with scanner deals. AI-assisted quantification from Siemens鈥� AI-Rad Companion or GE HealthCare鈥檚 Edison platform cuts radiologist reading time 30%鈥�40%, a critical benefit when staffing is tight. Vendors now price upgrades on a per-study or annual-license basis, creating resilient recurring revenue. Consumables such as radiopharmaceutical doses and quality-control phantoms ride on procedure volumes, which expand at the overall 6.28% CAGR. BWXT Medical鈥檚 domestic yttrium-90 and indium-111 production will further anchor recurring consumable revenue as isotope self-sufficiency improves.

By Radio-Isotope: Fluorine-18 Retains Primacy, Gallium-68 Surges

Fluorine-18 contributed 37.94% of isotope revenue in 2025 because FDG PET/CT occupies the oncology mainstream and the 110-minute half-life supports regional distribution. Technetium-99m remains indispensable for bone, cardiac, and renal scanning, yet supply risks continue until domestic molybdenum-99 output stabilizes. Gallium-68 is the fastest-growing isotope at a 10.33% CAGR and underpins PSMA and DOTATATE imaging. Health Canada鈥檚 approval of lutetium-177 PSMA-617 in 2022 cemented the theranostic pairing that drives diagnostic gallium-68 use. Provincial cyclotron projects will allow on-site gallium-68 generator production, improving access beyond Ontario. Rubidium-82 cardiac PET gains favor because it delivers 75% lower radiation than technetium-99m SPECT while avoiding cyclotron dependence. Investigational isotopes such as copper-64 and zirconium-89 are now in Phase II academic trials, setting the stage for diversified isotope portfolios after 2030.

Note: Segment shares of all individual segments available upon report purchase

By Application: Oncology Commands, Neurology Accelerates

Oncology absorbed 52.68% of application revenue in 2025 thanks to FDG PET/CT and accelerating PSMA PET utilization. Neurology is forecast to grow at 8.29% CAGR as amyloid and tau PET tracers gain reimbursement, enabling earlier Alzheimer鈥檚 differentiation. Cardiology sits second in share; the shift from SPECT to PET proceeds as rubidium-82 generators lower dose and improve accuracy. Endocrinology remains a smaller yet steady niche, rooted in iodine-based thyroid imaging and therapy. Infection and inflammation studies continue contracting as CT and MRI alternatives mature. Large provincial cancer-centers in British Columbia and Ontario have already embedded PSMA theranostics into routine pathways, underscoring oncology鈥檚 catalytic role for the Canada nuclear imaging market.

By End User: Hospitals Hold Lead, Academic Institutes Outpace Growth

Hospitals generated 61.53% of end-user revenue in 2025, reflecting single-payer referral patterns. Diagnostic imaging centers offer shorter waits but still face volume ceilings under provincial reimbursement caps. Academic and research institutes grow fastest at 8.12% CAGR because they secure federal grants and industry partnerships for total-body PET, theranostics, and novel radiopharmaceutical trials. The Canada nuclear imaging market share tilted toward hospitals will gradually narrow as academic centers commercialize innovations that downstream hospitals later adopt. Academic hubs also house new cyclotron facilities that distribute isotopes to regional hospitals, reinforcing their pivotal supply-chain role.

Note: Segment shares of all individual segments available upon report purchase

Geography Analysis

Ontario, Quebec, and British Columbia account for nearly 70% of Canada nuclear imaging market capacity because they host large population centers and academic medical networks. Ontario leads on absolute procedure volume, with Princess Margaret Cancer Centre and the Ottawa Hospital anchoring theranostic adoption. Quebec鈥檚 CHUM and McGill University Health Centre leverage in-house cyclotrons to support high tracer diversity. British Columbia鈥檚 USD 23.7 million University of British Columbia cyclotron, operational since 2026, positions the province as the western isotope hub, cutting delivery times for isotopes whose half-life is less than two hours. Alberta鈥檚 Calgary Radiopharmaceutical Centre, slated for completion in 2027, will serve Prairie provinces and trim dependency on Ontario. Atlantic provinces lean on Halifax鈥檚 Queen Elizabeth II Health Sciences Centre, where a 2024 digital SPECT/CT upgrade improved throughput and reduced technetium-99m dose, yet patients in rural communities still drive hundreds of kilometers for scans. Northern territories remain dependent on medical evacuations to southern centers because population density cannot justify on-site facilities.

Reimbursement policies shape regional growth. Ontario鈥檚 six-scanner expansion aimed for 2028 prioritizes northern and eastern communities, whereas British Columbia funnels nuclear-medicine funding through BC Cancer鈥檚 centralized network. Alberta maintains a mixed public-private model, allowing independent imaging centers to contract services, but logistics complexity increases for isotope supply. Technologist shortages further widen regional disparities: vacancy rates climb above 10% in Atlantic Canada, leading to longer appointment backlogs despite hardware upgrades. Decentralized cyclotron investment will alleviate some supply pressure by 2031, yet Ontario鈥檚 mature academic ecosystem retains first-mover advantage, maintaining the province鈥檚 status as the innovation hub of the Canada nuclear imaging market.